Last10K.com

Nuo Therapeutics, Inc. (AURX) SEC Filing 10-Q Quarterly Report for the period ending Thursday, March 31, 2022

SEC Filings

AURX Quarterly Reports

Nuo Therapeutics, Inc.

CIK: 1091596 Ticker: AURX
Document And Entity Information - shares
3 Months Ended
Mar. 31, 2022
May 06, 2022
Document Information [Line Items]  
Entity Central Index Key0001091596 
Entity Registrant NameNuo Therapeutics, Inc. 
Amendment Flagfalse 
Current Fiscal Year End Date--12-31 
Document Fiscal Period FocusQ1 
Document Fiscal Year Focus2022 
Document Type10-Q 
Document Quarterly Reporttrue 
Document Period End DateMar. 31, 2022 
Document Transition Reportfalse 
Entity File Number000-28443 
Entity Incorporation, State or Country CodeDE 
Entity Tax Identification Number23-3011702 
Entity Address, Address Line One8285 El Rio, Suite 190 
Entity Address, City or TownHouston 
Entity Address, State or ProvinceTX 
Entity Address, Postal Zip Code77054 
City Area Code346 
Local Phone Number396-4770 
Entity Current Reporting StatusNo 
Entity Interactive Data CurrentYes 
Entity Filer CategoryNon-accelerated Filer 
Entity Small Businesstrue 
Entity Emerging Growth Companyfalse 
Entity Shell Companyfalse 
Entity Common Stock, Shares Outstanding 40,674,205

View differences made from one quarter to another to evaluate Nuo Therapeutics, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Nuo Therapeutics, Inc..

Continue

Assess how Nuo Therapeutics, Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Nuo Therapeutics, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2022 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

SEC Filing Tools

Financial Statements, Disclosures and Schedules

Inside this 10-Q Quarterly Report

Document And Entity Information
Condensed Consolidated Balance Sheets (Current Period Unaudited)
Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals)
Condensed Consolidated Statements Of Cash Flows (Unaudited)
Condensed Consolidated Statements Of Changes In Stockholders' Equity (Unaudited)
Condensed Consolidated Statements Of Operations (Unaudited)
Note 1 - Description Of Business
Note 2 - Recapitalization
Note 2 - Recapitalization (Details Textual)
Note 3 - Liquidity And Summary Of Significant Accounting Principles
Note 3 - Liquidity And Summary Of Significant Accounting Principles (Details Textual)
Note 3 - Liquidity And Summary Of Significant Accounting Principles (Tables)
Note 3 - Liquidity And Summary Of Significant Accounting Principles - Anti-Dilutive Securities Excluded From The Computation Of Diluted Earnings (Loss) Per Share (Details)
Note 3 - Liquidity And Summary Of Significant Accounting Principles - Summary Stock Option Valuation Assumptions (Details)
Note 4 - Property And Equipment
Note 4 - Property And Equipment (Details Textual)
Note 4 - Property And Equipment (Tables)
Note 4 - Property And Equipment - Property And Equipment, Net (Details)
Note 5 - Stock Purchase Warrants
Note 5 - Stock Purchase Warrants (Details Textual)
Note 5 - Stock Purchase Warrants (Tables)
Note 5 - Stock Purchase Warrants - Outstanding Stock Purchase Warrants (Details)
Note 6 - Equity And Stock-Based Compensation
Note 6 - Equity And Stock-Based Compensation (Details Textual)
Note 6 - Equity And Stock-Based Compensation (Tables)
Note 6 - Equity And Stock-Based Compensation - Stock Option Activity (Details)
Note 7 - Commitments And Contingencies
Note 7 - Commitments And Contingencies (Details Textual)
Note 7 - Commitments And Contingencies (Tables)
Note 7 - Commitments And Contingencies - Future Undiscounted Cash Flows (Details)
Note 8 - Subsequent Events
Note 8 - Subsequent Events (Details Textual)
Significant Accounting Policies (Policies)

Material Contracts, Statements, Certifications & more

Nuo Therapeutics, Inc. provided additional information to their SEC Filing as exhibits

Ticker: AURX
CIK: 1091596
Form Type: 10-Q Quarterly Report
Accession Number: 0001437749-22-012650
Submitted to the SEC: Mon May 16 2022 4:38:04 PM EST
Accepted by the SEC: Mon May 16 2022
Period: Thursday, March 31, 2022
Industry: Surgical And Medical Instruments And Apparatus

External Resources:
Stock Quote
Social Media

Bookmark the Permalink:
https://last10k.com/sec-filings/aurx/0001437749-22-012650.htm